10x Genomics gets injunction against Parse Biosciences' ATAC Products
Seeking Alpha News (Mon, 3-Mar 4:43 PM ET)
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products
PRNewswire (Mon, 3-Mar 4:05 PM ET)
PRNewswire (Sun, 23-Feb 11:30 AM ET)
10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference
PRNewswire (Tue, 18-Feb 4:05 PM ET)
PRNewswire (Wed, 12-Feb 4:05 PM ET)
PRNewswire (Thu, 6-Feb 8:30 AM ET)
10x Genomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025
PRNewswire (Tue, 28-Jan 4:05 PM ET)
10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2024 Results
PRNewswire (Sun, 12-Jan 12:00 PM ET)
10x Genomics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PRNewswire (Thu, 2-Jan 4:05 PM ET)
PRNewswire (Mon, 23-Dec 4:05 PM ET)
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
10X Genomics trades on the NASDAQ stock market under the symbol TXG.
As of March 4, 2025, TXG stock price climbed to $10.34 with 2,260,641 million shares trading.
TXG has a beta of 0.99, meaning it tends to be less sensitive to market movements. TXG has a correlation of 0.05 to the broad based SPY ETF.
TXG has a market cap of $1.26 billion. This is considered a Small Cap stock.
Last quarter 10X Genomics reported $165 million in Revenue and -$.40 earnings per share. This beat revenue expectation by $41,000 and missed earnings estimates by -$.29.
In the last 3 years, TXG traded as high as $83.34 and as low as $9.27.
The top ETF exchange traded funds that TXG belongs to (by Net Assets): ARKK, VTI, VB, ARKG, VXF.
TXG has underperformed the market in the last year with a price return of -77.3% while the SPY ETF gained +14.4%. TXG has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -34.6% and -16.0%, respectively, while the SPY returned -3.7% and -4.9%, respectively.
TXG support price is $9.36 and resistance is $10.34 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TXG shares will trade within this expected range on the day.